IGC Pharma (IGC) Profit After Tax (2010 - 2025)

IGC Pharma (IGC) has reported Profit After Tax for 16 consecutive years, with -$1.8 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Profit After Tax fell 6.24% year-over-year to -$1.8 million; the TTM figure through Sep 2025 stood at -$6.5 million (up 48.23% YoY), while the FY2026 annual figure was -$2.4 million, up 66.27% from the prior year.
• Profit After Tax fell to -$1.8 million in Q3 2025 per IGC's latest filing, from -$1.6 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$1.2 million in Q1 2025 and bottomed at -$6.7 million in Q1 2022.
• Historically, Profit After Tax has averaged -$2.8 million across 5 years, with a median of -$2.4 million in 2021.
• Annual changes were most pronounced in 2021 — Profit After Tax plunged 185.41% — and 2024, when it jumped 66.85%.
• IGC Pharma's Profit After Tax stood at -$2.4 million in 2021, then rose by 2.98% to -$2.3 million in 2022, then slumped by 141.17% to -$5.6 million in 2023, then surged by 66.85% to -$1.8 million in 2024, then grew by 0.38% to -$1.8 million in 2025.
• Business Quant data shows IGC's Profit After Tax at -$1.8 million in Q3 2025, -$1.6 million in Q2 2025, and -$1.2 million in Q1 2025.